Loading...

Catalent

DB:0C8
Snowflake Description

Reasonable growth potential with acceptable track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
0C8
DB
$7B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. The last earnings update was 79 days ago. More info.


Add to Portfolio Compare Print
  • Catalent has significant price volatility in the past 3 months.
0C8 Share Price and Events
7 Day Returns
5.8%
DB:0C8
0.1%
DE Pharmaceuticals
0.8%
DE Market
1 Year Returns
17.3%
DB:0C8
-20.9%
DE Pharmaceuticals
-4.5%
DE Market
0C8 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Catalent (0C8) 5.8% 11.4% 26.9% 17.3% 51.8% -
DE Pharmaceuticals 0.1% 1.9% -1.5% -20.9% -24.3% 6.9%
DE Market 0.8% 6.9% 8.1% -4.5% 10.4% 13.9%
1 Year Return vs Industry and Market
  • 0C8 outperformed the Pharmaceuticals industry which returned -20.9% over the past year.
  • 0C8 outperformed the Market in Germany which returned -4.5% over the past year.
Price Volatility
0C8
Industry
5yr Volatility vs Market

Value

 Is Catalent undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Catalent to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Catalent.

DB:0C8 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 8 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5.9%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:0C8
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.73
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.732 (1 + (1- 21%) (33.83%))
0.952
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.95
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (0.952 * 5.96%)
5.9%

Discounted Cash Flow Calculation for DB:0C8 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Catalent is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:0C8 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 5.9%)
2019 356.00 Analyst x1 336.17
2020 336.00 Analyst x1 299.61
2021 392.99 Est @ 16.96% 330.90
2022 439.91 Est @ 11.94% 349.78
2023 476.98 Est @ 8.43% 358.13
2024 505.44 Est @ 5.97% 358.36
2025 526.90 Est @ 4.25% 352.76
2026 542.92 Est @ 3.04% 343.24
2027 554.84 Est @ 2.2% 331.24
2028 563.75 Est @ 1.61% 317.81
Present value of next 10 years cash flows $3,378.01
DB:0C8 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $563.75 × (1 + 0.23%) ÷ (5.9% – 0.23%)
$9,963.67
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $9,963.67 ÷ (1 + 5.9%)10
$5,616.96
DB:0C8 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $3,378.01 + $5,616.96
$8,994.97
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $8,994.97 / 145.71
$61.73
DB:0C8 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:0C8 represents 0.88763x of NYSE:CTLT
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.88763x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 61.73 x 0.88763
€54.80
Value per share (EUR) From above. €54.80
Current discount Discount to share price of €39.62
= -1 x (€39.62 - €54.80) / €54.80
27.7%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Catalent is available for.
Intrinsic value
28%
Share price is €39.62 vs Future cash flow value of €54.8
Current Discount Checks
For Catalent to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Catalent's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Catalent's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Catalent's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Catalent's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:0C8 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $0.99
NYSE:CTLT Share Price ** NYSE (2019-04-25) in USD $44.63
Germany Pharmaceuticals Industry PE Ratio Median Figure of 6 Publicly-Listed Pharmaceuticals Companies 27.01x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 20.1x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Catalent.

DB:0C8 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NYSE:CTLT Share Price ÷ EPS (both in USD)

= 44.63 ÷ 0.99

45.25x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Catalent is overvalued based on earnings compared to the DE Pharmaceuticals industry average.
  • Catalent is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does Catalent's expected growth come at a high price?
Raw Data
DB:0C8 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 45.25x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts
26.7%per year
Europe Pharmaceuticals Industry PEG Ratio Median Figure of 35 Publicly-Listed Pharmaceuticals Companies 1.8x
Germany Market PEG Ratio Median Figure of 268 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

DB:0C8 PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 45.25x ÷ 26.7%

1.7x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Catalent is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Catalent's assets?
Raw Data
DB:0C8 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $10.73
NYSE:CTLT Share Price * NYSE (2019-04-25) in USD $44.63
Germany Pharmaceuticals Industry PB Ratio Median Figure of 9 Publicly-Listed Pharmaceuticals Companies 2.43x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:0C8 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NYSE:CTLT Share Price ÷ Book Value per Share (both in USD)

= 44.63 ÷ 10.73

4.16x

* Primary Listing of Catalent.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Catalent is overvalued based on assets compared to the DE Pharmaceuticals industry average.
X
Value checks
We assess Catalent's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Catalent has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Catalent expected to perform in the next 1 to 3 years based on estimates from 8 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
26.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Catalent expected to grow at an attractive rate?
  • Catalent's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Catalent's earnings growth is expected to exceed the Germany market average.
  • Catalent's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:0C8 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:0C8 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts 26.7%
DB:0C8 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 8 Analysts 5.8%
Germany Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 19.7%
Germany Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 4.8%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.8%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:0C8 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:0C8 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-06-30 2,849 265 1
2020-06-30 2,697 436 205 5
2019-06-30 2,536 485 157 8
DB:0C8 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 2,488 283 136
2018-09-30 2,471 332 65
2018-06-30 2,463 375 84
2018-03-31 2,395 371 63
2017-12-31 2,300 380 70
2017-09-30 2,177 335 109
2017-06-30 2,075 300 110
2017-03-31 1,991 233 106
2016-12-31 1,896 180 91
2016-09-30 1,867 159 104
2016-06-30 1,848 155 112
2016-03-31 1,826 199 207

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Catalent's earnings are expected to grow significantly at over 20% yearly.
  • Catalent's revenue is expected to grow by 5.8% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:0C8 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below

All data from Catalent Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:0C8 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-06-30 1.79 1.79 1.79 1.00
2020-06-30 1.30 1.50 1.05 4.00
2019-06-30 0.99 1.12 0.87 5.00
DB:0C8 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 0.99
2018-09-30 0.48
2018-06-30 0.64
2018-03-31 0.49
2017-12-31 0.55
2017-09-30 0.87
2017-06-30 0.88
2017-03-31 0.85
2016-12-31 0.73
2016-09-30 0.83
2016-06-30 0.89
2016-03-31 1.66

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Catalent is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Catalent's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Catalent has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Catalent performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Catalent's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Catalent's year on year earnings growth rate has been positive over the past 5 years.
  • Catalent's 1-year earnings growth exceeds its 5-year average (95.6% vs 10.6%)
  • Catalent's earnings growth has exceeded the DE Pharmaceuticals industry average in the past year (95.6% vs 22%).
Earnings and Revenue History
Catalent's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Catalent Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:0C8 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 2,488.00 136.30 463.30 4.50
2018-09-30 2,471.30 65.40 454.40 5.00
2018-06-30 2,463.40 83.60 445.10 6.30
2018-03-31 2,395.00 62.70 430.60 6.80
2017-12-31 2,299.70 69.70 414.20 7.30
2017-09-30 2,177.10 109.00 395.60 7.30
2017-06-30 2,075.40 109.80 386.60 7.00
2017-03-31 1,990.70 106.10 372.70 7.10
2016-12-31 1,896.10 90.80 365.40 6.90
2016-09-30 1,867.30 104.20 361.50 7.50
2016-06-30 1,848.10 111.50 350.50 7.60
2016-03-31 1,826.00 207.20 345.90 9.60
2015-12-31 1,834.60 228.00 332.80 10.20
2015-09-30 1,835.50 243.90 327.20 11.00
2015-06-30 1,830.80 212.10 325.10 12.20
2015-03-31 1,840.30 85.50 315.40 13.60
2014-12-31 1,846.80 62.40 320.40 15.30
2014-09-30 1,831.70 -2.90 318.20 16.90
2014-06-30 1,827.70 18.90 317.30 17.50
2014-03-31 1,813.30 1.90 328.40 16.70
2013-12-31 1,807.20 -20.40 325.50 15.70
2013-09-30 1,802.60 -29.40 324.70 15.20
2013-06-30 1,800.30 -50.80 326.10 14.50
2012-06-30 1,694.80 16.90 316.20 16.90

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Catalent has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Catalent used its assets less efficiently than the DE Pharmaceuticals industry average last year based on Return on Assets.
  • Catalent's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Catalent's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Catalent has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Catalent's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Catalent's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Catalent is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Catalent's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Catalent's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is not covered by short term assets, assets are 0.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Catalent Company Filings, last reported 3 months ago.

DB:0C8 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 1,563.00 2,199.90 207.90
2018-09-30 1,529.40 2,279.10 266.10
2018-06-30 1,086.70 2,721.30 410.20
2018-03-31 1,068.40 2,777.10 402.20
2017-12-31 1,005.50 2,742.40 339.30
2017-09-30 1,038.80 2,106.80 614.80
2017-06-30 723.50 2,079.70 306.90
2017-03-31 642.70 2,049.00 268.80
2016-12-31 588.00 2,024.40 255.80
2016-09-30 614.50 1,937.30 139.90
2016-06-30 635.90 1,860.50 138.60
2016-03-31 602.90 1,870.80 133.90
2015-12-31 607.40 1,872.70 115.50
2015-09-30 603.00 1,883.90 151.40
2015-06-30 639.80 1,880.80 151.30
2015-03-31 472.70 1,881.80 116.10
2014-12-31 496.30 1,934.20 84.10
2014-09-30 507.30 1,816.70 63.20
2014-06-30 -367.30 2,710.60 74.40
2014-03-31 -395.90 2,701.20 55.70
2013-12-31 -409.20 2,730.80 64.20
2013-09-30 -382.10 2,703.70 95.80
2013-06-30 -410.30 2,691.60 106.40
2012-06-30 -350.70 2,706.70 139.00
  • Catalent's level of debt (140.7%) compared to net worth is high (greater than 40%).
  • Catalent had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
  • Debt is not well covered by operating cash flow (12.9%, less than 20% of total debt).
  • Interest payments on debt are not well covered by earnings (EBIT is 2.7x annual interest expense, ideally 3x coverage).
X
Financial health checks
We assess Catalent's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Catalent has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Catalent's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Catalent dividends. Estimated to be 0% next year.
If you bought €2,000 of Catalent shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Catalent's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Catalent's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:0C8 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
Germany Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 3.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:0C8 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2021-06-30 0.00 1.00
2020-06-30 0.00 3.00
2019-06-30 0.00 3.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Catalent has not reported any payouts.
  • Unable to verify if Catalent's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Catalent's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Catalent has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Catalent's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Catalent's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Catalent afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Catalent has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Catalent's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
John Chiminski
COMPENSATION $8,526,868
AGE 54
TENURE AS CEO 10.1 years
CEO Bio

Mr. John R. Chiminski has been the Chief Executive Officer at Catalent, Inc. since March 2009 and has been its Chairman since October 25, 2016. He also served as President at Catalent, Inc. until February, 2019. Mr. Chiminski has been the Chief Executive Officer and President at Catalent Pharma Solutions, Inc. since March 17, 2009. He has been President and Chief Executive Officer of Juniper Pharmaceuticals, Inc. since August 14, 2018. He serves as the Chief Executive Officer and President of Catalent Pharma Solutions, LLC. He has Substantial expertise in advising and managing companies in various segments of the healthcare industry, and Significant experience overseeing the day-to-day business operations of a healthcare company. He served as a variety of senior management positions at GE Healthcare. He served as the Chief Executive Officer and President of Medical Diagnostics of GE Healthcare Ltd., from October 2007 to March 2009. Mr. Chiminski joined GE Medical Systems in 1988 on the MMP Program and held a series of cross-functional leadership positions in both manufacturing and engineering, including a GE Medical Systems assignment in France. He served as Global Manager of Vascular Systems Engineering of GE Medical. Mr. Chiminski has diversified business background that includes lean manufacturing, supply chain, research and development, customer service and global business management, with a focus on customers and growth. In 1998, he served as General Manager of Global CT Engineering. He joined Catalent after more than 20 years of experience at GE Healthcare in engineering, operations and senior leadership roles. He served as General Manager of Customer Advocacy since August 2000 and also since September 2001. He served as Vice President and General Manager of Americas Service GE Medical Systems. In January 2004, his role was expanded to include Global Healthcare Services. Since March 2005, he served as Vice President and General Manager of Global MR Business of GE healthcare. From 2007 to 2009, Mr. Chiminski served as President and Chief Executive Officer of GE Medical Diagnostics, a global business with sales of $1.9 billion. From 2005 to 2007, he served as Vice President and General Manager of GE Healthcare’s Global Magnetic Resonance Business and from 2001 to 2005, as Vice President and General Manager of Global Healthcare Services. He serves on the Board of Trustees for the HealthCare Institute of New Jersey. He serves as the Chairman of Catalent Pharma Solutions, Inc. He serves as a Director of Graham Packaging Holdings Company and Graham Packaging Company, L.P. He has been a Director of Catalent, Inc. since February 2009; Catalent Pharma Solutions, Inc. since March 17, 2009 and Graham Packaging Company, Inc. since March 17, 2009. He served as a Director of DJO Finance LLC from March 22, 2012 to October 28, 2015. He served as a Director of DJO Global Inc. until October 28, 2015. Mr. Chiminski received a BS from Michigan State University in 1986 and an M.S. from Purdue University, both in electrical engineering, as well as a Master’s Degree in Management from the Kellogg School of Management at Northwestern University 1996.

CEO Compensation
  • John's compensation has increased by more than 20% in the past year.
  • John's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Catalent management team in years:

1.5
Average Tenure
52
Average Age
  • The average tenure for the Catalent management team is less than 2 years, this suggests a new team.
Management Team

John Chiminski

TITLE
Chairman & CEO
COMPENSATION
$9M
AGE
54
TENURE
10.1 yrs

Wetteny Joseph

TITLE
Senior VP & CFO
COMPENSATION
$2M
AGE
46
TENURE
1.2 yrs

Steven Fasman

TITLE
Senior VP
COMPENSATION
$2M
AGE
55

Jonathan Arnold

TITLE
President of Oral Drug Delivery Business Unit
COMPENSATION
$2M
AGE
52
TENURE
1.5 yrs

Alessandro Maselli

TITLE
President & COO
AGE
46
TENURE
0.2 yrs

Tom Castellano

TITLE
VP of Finance & Investor Relations and Treasurer
TENURE
4.2 yrs

Lance Miyamoto

TITLE
Senior Vice President of Human Resources
AGE
63
TENURE
8.1 yrs

Barry Littlejohns

TITLE
President of Biologics & Specialty Drug Delivery
COMPENSATION
$1M
AGE
52
TENURE
1.5 yrs

Scott Gunther

TITLE
Senior Vice President of Quality & Regulatory Affairs
AGE
51
TENURE
1.9 yrs

Tedd Green

TITLE
Senior Vice President of Catalent Bloomington
TENURE
1.5 yrs
Board of Directors Tenure

Average tenure and age of the Catalent board of directors in years:

3.7
Average Tenure
61.5
Average Age
  • The tenure for the Catalent board of directors is about average.
Board of Directors

John Chiminski

TITLE
Chairman & CEO
COMPENSATION
$9M
AGE
54
TENURE
2.5 yrs

Jack Stahl

TITLE
Lead Director
COMPENSATION
$281K
AGE
65
TENURE
2.5 yrs

Greg Lucier

TITLE
Independent Director
COMPENSATION
$242K
AGE
54
TENURE
4 yrs

Marty Carroll

TITLE
Independent Director
COMPENSATION
$249K
AGE
69
TENURE
3.8 yrs

Donald Morel

TITLE
Independent Director
COMPENSATION
$260K
AGE
60
TENURE
3.4 yrs

John Greisch

TITLE
Director
COMPENSATION
$95K
AGE
63
TENURE
1.2 yrs

Rolf Classon

TITLE
Independent Director
COMPENSATION
$250K
AGE
73
TENURE
5.3 yrs

Carolyn Bertozzi

TITLE
Member of Scientfic & Advisory Board
AGE
51
TENURE
3.7 yrs

Barry Buckland

TITLE
Member of Advisory Board
AGE
70
TENURE
3.7 yrs

Mike Buckley

TITLE
Member of Advisory Board
AGE
57
TENURE
3.7 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
13. Nov 18 Buy John Greisch Individual 08. Nov 18 08. Nov 18 13,000 €32.94 €428,205
17. Sep 18 Buy Donald Morel Individual 13. Sep 18 13. Sep 18 10,000 €36.82 €368,209
X
Management checks
We assess Catalent's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Catalent has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics and Specialty Drug Delivery segment formulates, develops, and manufactures small molecule and biologic drug products in prefilled syringes, vials and cartridges, blow-fill-seal unit doses, and injectable formats; develops biologic cell lines; manufactures biologic drug substances; and offers bioanalytical development and testing services. The Oral Drug Delivery segment formulates, develops, and manufactures oral dosage forms using proprietary and conventional drug delivery technologies, such as Zydis, OptiDose CR, OptiPact, OptiForm API and Solution Suite, Pharmatek SD Spray Drying, OptiMelt hot melt extrusion, Micron particle size reduction, and FlexDose; and provides stick pack formulation and filling, and analytical development and testing services. The Clinical Supply Services segment offers Manufacturing, packaging, labeling, storage, distribution, and inventory management for drugs and biologics clinical trials; FastChain demand-led clinical supply services; clinical e-solutions and informatics; and comparator sourcing services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was founded in 2007 and is headquartered in Somerset, New Jersey.

Details
Name: Catalent, Inc.
0C8
Exchange: DB
Founded: 2007
$5,838,297,064
145,706,760
Website: http://www.catalent.com
Address: Catalent, Inc.
14 Schoolhouse Road,
Somerset,
New Jersey, 08873,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NYSE CTLT Common Stock New York Stock Exchange US USD 31. Jul 2014
DB 0C8 Common Stock Deutsche Boerse AG DE EUR 31. Jul 2014
Number of employees
Current staff
Staff numbers
10,700
Catalent employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/25 22:29
End of day share price update: 2019/04/25 00:00
Last estimates confirmation: 2019/04/17
Last earnings filing: 2019/02/05
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.